• Publications
  • Influence
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized
  • Y. Shi, L. Wang, +25 authors Y. Sun
  • Medicine
  • Annals of oncology : official journal of the…
  • 1 October 2017
Background Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In thisExpand
  • 94
  • 7
Clinical response to apatinib monotherapy in advanced non‐small cell lung cancer
Apatinib, an oral tyrosine kinase inhibitor mainly targeting VEGFR‐2, exerts both antiangiogenesis and antiproliferation effects. Apatinib shows clinical benefit in advanced non‐small cell lungExpand
  • 24
  • 1
Clostridium difficile infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer chemotherapy.
The purpose of this study was to determine the presence of Clostridium difficile infection (CDI) and risk factors for infection in hospitalized patients with diarrhea in a cancer hospital in Beijing,Expand
  • 19
  • 1
[Prognostic significance of inflammatory indicators for advanced-stage diffuse large B-cell lymphoma].
Objective: To explore the prognostic significance of inflammatory indicator, neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), for advanced-stage diffuse large B-cellExpand
  • 2
  • 1
Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
Osimertinib is a novel, irreversible, mutant‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. Here, we report a womanExpand
  • 2
  • 1
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
Purpose: Patients with alveolar soft part sarcoma (ASPS) are rare and have few treatment options. We assessed the activity of geptanolimab (GB226), a fully humanized programmed cell death protein 1Expand
  • 2
  • 1
[Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
  • L. Gui, X. He, +6 authors Y. Shi
  • Medicine
  • Zhonghua xue ye xue za zhi = Zhonghua xueyexue…
  • 14 September 2016
Objective: To evaluate the clinical features and outcomes of HIV-negtive plasmablastic lymphoma (PBL). Methods: Nine patients with HIV-negtive PBL were diagnosed and treated between January 2006 andExpand
  • 1
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
  • H. Nokihara, S Lu, +17 authors T. Tamura
  • Medicine
  • Annals of oncology : official journal of the…
  • 29 September 2017
Abstract Background Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. WeExpand
  • 42
Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study
BackgroundBevacizumab is a monoclonal antibody with high antitumor activity against malignant diseases. Previous studies have demonstrated the efficacy of first-line bevacizumab combination therapyExpand
  • 14